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Abstract
Background: Conventional tests for tuberculous pleuritis have several limitations. A variety of new, rapid tests
such as nucleic acid amplification tests – including polymerase chain reaction – have been evaluated in recent
times. We conducted a systematic review to determine the accuracy of nucleic acid amplification (NAA) tests in
the diagnosis of tuberculous pleuritis.
Methods: A systematic review and meta-analysis of 38 English and Spanish articles (with 40 studies), identified
via searches of six electronic databases, hand searching of selected journals, and contact with authors, experts,
and test manufacturers. Sensitivity, specificity, and other measures of accuracy were pooled using random effects
models. Summary receiver operating characteristic curves were used to summarize overall test performance.
Heterogeneity in study results was formally explored using subgroup analyses.
Results: Of the 40 studies included, 26 used in-house ("home-brew") tests, and 14 used commercial tests.
Commercial tests had a low overall sensitivity (0.62; 95% confidence interval [CI] 0.43, 0.77), and high specificity
(0.98; 95% CI 0.96, 0.98). The positive and negative likelihood ratios for commercial tests were 25.4 (95% CI 16.2,
40.0) and 0.40 (95% CI 0.24, 0.67), respectively. All commercial tests had consistently high specificity estimates;
the sensitivity estimates, however, were heterogeneous across studies. With the in-house tests, both sensitivity
and specificity estimates were significantly heterogeneous. Clinically meaningful summary estimates could not be
determined for in-house tests.
Conclusions: Our results suggest that commercial NAA tests may have a potential role in confirming (ruling in)
tuberculous pleuritis. However, these tests have low and variable sensitivity and, therefore, may not be useful in
excluding (ruling out) the disease. NAA test results, therefore, cannot replace conventional tests; they need to
be interpreted in parallel with clinical findings and results of conventional tests. The accuracy of in-house nucleic
acid amplification tests is poorly defined because of heterogeneity in study results. The clinical applicability of in-
house NAA tests remains unclear.
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Background
In the context of the human immunodeficiency virus
(HIV) epidemic, clinicians frequently encounter extrapul-
monary and disseminated forms of tuberculosis (TB) [1-
3]. In the USA, nearly 20% of the TB cases are extra-pul-
monary [2]. In England and Wales, 38% of the TB cases
are extrapulmonary [3]. Tuberculous pleuritis is a com-
mon manifestation of extrapulmonary TB [4]. TB is the
most common cause of pleural effusion in many coun-
tries [4]. For example, studies from Spain [5], Malaysia
[6], and Saudi Arabia [7] showed that TB accounted for
25%, 44%, and 37% of all effusions respectively. In the
USA, the annual incidence of tuberculous pleuritis has
been estimated to be about 1000 cases, and approxi-
mately one in 300 patients with TB will have tuberculous
pleuritis [4,8]. The incidence of tuberculous effusions may
be higher in patients with HIV infection [9].
Conventional diagnostic tests include microscopy of the
pleural fluid, culture of pleural fluid, sputum pleural tis-
sue, and pleural biopsy [4]. These tests have limitations.
Microscopy of the pleural fluid is rarely positive (<5%)
[10-12]. Culture of pleural fluid has low sensitivity (24%
– 58%), and results are not available for weeks [11-13].
Biopsy of pleural tissue, and culture of biopsy material are
widely held to be the best methods of confirming the
diagnosis [4,10,12]. This combination may lead to the
diagnosis 86% of the time [10]. Although not perfect, cul-
ture and/or biopsy, therefore, are widely considered the
standard of diagnosis [4,10]. However, pleural biopsy is
invasive, operator-dependent, and technically difficult
(particularly in children) [14].
Because of the limitations of conventional tests, newer
and rapid tests such as nucleic acid amplification tests –
including polymerase chain reaction (PCR) – have been
evaluated. Because of their high sensitivity and specificity
in smear-positive respiratory specimens, these tests are
now used – mainly in developed countries – for the direct
detection of M. tuberculosis complex in respiratory speci-
mens [15,16]. NAA tests are categorized as commercial or
in-house ("home-brew") tests. Commercial tests include
the Amplified Mycobacterium tuberculosis Direct Test®
(MTD) (Gen-Probe Inc, San Diego, CA), the Amplicor®
MTB tests (Roche Molecular Systems, Branchburg, NJ),
and the recently discontinued LCx® test (Abbott Laborato-
ries, Abbott Park, IL). In the USA, the Amplicor test is
licensed for use in smear-positive respiratory specimens;
the MTD test is approved for smear-positive as well as
smear-negative respiratory specimens [16]. No commer-
cial test is licensed for use in non-respiratory specimens.
We conducted this systematic review and meta-analysis to
determine the overall accuracy of NAA tests in the diagno-
sis of tuberculous pleuritis, and to identify factors associ-
ated with heterogeneity of results between studies.
Methods
Search strategy
We searched the following databases: PubMed (1985 –
January 2003), EMBASE (1988–2002), Web of Science
(1990–2002), BIOSIS (1993–2002), Cochrane Library
(2002; Issue 2), and LILACS (1990–2002). The Journal of
Clinical Microbiology, a high-yield journal for TB diagnostic
studies, was also hand-searched separately. All searches
were up to date as of August 2002. The PubMed search
was updated in January 2003. The search terms used were:
tuberculosis,  Mycobacterium tuberculosis, nucleic acid
amplification techniques, polymerase chain reaction, sen-
sitivity and specificity, and accuracy. Experts in the field
were contacted. Bibliographies from the included studies
and relevant review articles were screened. We obtained
lists of citations from companies that manufacture com-
mercial tests. Although no language restrictions were
imposed initially, for the full-text review and final analysis
our resources only permitted review of English and Span-
ish articles. Conference abstracts were excluded because of
the limited data presented in them.
Study selection
Our search strategy was designed to include all published
studies on NAA tests for the direct detection of M. tubercu-
losis in pleural fluid specimens. For inclusion, a study had
to:
1. report a comparison of an NAA test against a reference
standard, and provide data necessary for the computation
of both sensitivity and specificity;
2. include at least 10 pleural fluid specimens (since stud-
ies with very few specimens are vulnerable to selection
bias [17])
Studies on use of NAA tests on pleural biopsy and/or
cytology specimens were excluded.
Two reviewers (MP and LLF) independently judged study
eligibility while screening the citations. Disagreements
were resolved by consensus. A list of excluded studies and
a log of reasons for exclusion are available from the
authors upon request.
Data extraction and quality assessment
Data extraction was performed by two reviewers. One
reviewer (MP) extracted the data from all English studies.
Another reviewer (LLF) extracted data from all Spanish
articles. The second reviewer (LLF) also independently
extracted data from a subset (36%) of the English articles,
in order to determine the inter-rater agreement. The
abstracted data included methodological quality, partici-
pant characteristics, test methods, and outcome data.BMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/6
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Quality assessment was performed using methods
adapted from two guidelines on systematic reviews of
diagnostic studies [17,18]. For each study, the following
quality criteria were scored as fulfilled or not: 1) Inde-
pendent comparison of NAA test against reference stand-
ard; 2) Cross-sectional design (versus case-control design)
; 3) Blinded (single or double) interpretation of test and
reference standard results; 4) Consecutive or random sam-
pling of patients; 5) Prospective data collection; 6) Inclu-
sion of at least 10 specimens/patients with confirmed
tuberculous pleuritis. If no data on the above criteria were
reported in the primary studies, we requested the informa-
tion from the authors. For the purposes of analysis,
responses coded as "not reported" were grouped together
with "not met." A high quality study was arbitrarily
defined as that which met at least 5/6 criteria; a medium
quality met 3 or 4 of the 6 criteria; and a low quality study
met less than 3/6 criteria. Since discrepant analysis (where
discordant results between NAA test and reference test
results are resolved, post-hoc, using clinical data) may be a
potential source of bias, we preferentially included unre-
solved data.
Statistical analysis and data synthesis
We used standard methods recommended for meta-anal-
yses of diagnostic test evaluations [17-19]. Analyses were
performed using Meta-Test [20], and Stata version 8 (Stata
Corporation, Texas). We computed the following meas-
ures of test accuracy for each study: sensitivity [true posi-
tive rate (TPR)], specificity [1-false positive rate (FPR)],
positive likelihood ratio (LR+), negative likelihood ratio
(LR-), and diagnostic odds ratio (DOR). These measures
were pooled using the random effects model [17-19].
Each study in the meta-analysis contributed a pair of
numbers: TPR and FPR. Since TPR and FPR are not inde-
pendent, we summarized their joint distribution by con-
structing a summary receiver operating characteristic
(SROC) curve [21]. Unlike a traditional ROC plot used to
explore the effect of varying thresholds (cut-points) on
TPR and FPR in a single study, each data point in the
SROC plot represents a separate study the meta-analysis.
The SROC curve (and area under the curve) represents the
overall performance of the test, and depicts the trade off
between sensitivity and specificity. A symmetric curve sug-
gests that the variability in accuracy between studies is
explained, in part, by differences in thresholds employed
by the studies.
Heterogeneity in meta-analyses refers to the degree of var-
iability in results across studies. We used the Chi-square
and Fisher's exact tests to detect statistically significant
heterogeneity. Stratified (subgroup) analyses were used to
identify study design and test-related factors responsible
for heterogeneity in test accuracy. Studies using commer-
cial tests were analyzed separately from those using in-
house tests. Studies with commercial tests were further
stratified by type of test (brand). Finally, since publication
bias is of concern for meta-analyses of diagnostic studies
[22], we tested for the potential presence of this bias using
funnel plots and the Egger test [23].
Results
Description of included studies
Figure 1 outlines our study selection process. Thirty-eight
articles [24-61] were included in the meta-analysis. Four
articles were in Spanish [26,37,39,44]. Two articles
reported evaluations of more than one NAA test against a
common reference standard [30,57]. Each such test com-
parison was counted as a separate study. Thus, the total
number of test comparisons (hereafter referred to as stud-
ies) was 40. Of these, 14 (35%) were studies of commer-
cial tests, and 26 (65%) were of in-house tests. The
average (median) sample size of each study in the meta-
analysis was 60 pleural specimens or subjects, with a
range of 15 to 375.
Study characteristics and quality
The mean inter-rater agreement between the two review-
ers for items in the quality checklist was 0.86. Our initial
data were affected by incomplete reporting in the primary
studies. We contacted the authors via email, and obtained
additional data for 25/40 (63%) included studies. Tables
1 and 2 present the descriptive data from studies with
commercial and in-house tests, respectively. The tables
present data on study quality, along with sample size, sen-
sitivity and specificity estimates. In the commercial tests
subgroup (Table 1), 36%, 50%, and 14% of the studies
were of high, medium and low quality, respectively. In the
in-house tests subgroup (Table 2), 39%, 42%, and 19% of
the studies were of high, medium and low quality, respec-
tively. Tables 1 and 2 show the variability in study quality
and variability in NAA protocols employed. Although a
variety of reference tests (or combinations of reference
tests) were used, culture alone, or a combination of cul-
ture plus biopsy/microscopy/clinical data were used in 39
of the 40 studies.
Diagnostic accuracy of commercial tests
Figure 2(A) displays the sensitivity and specificity esti-
mates from each of the 14 studies using commercial tests,
stratified by type (brand) of test. Almost all studies had
specificity estimates close to 1.0. In contrast, sensitivity
estimates were lower and heterogeneous (range 0.20–
1.0). Figure 3(A) shows the SROC curve for the commer-
cial tests. The regression line does not trace out a typical
ROC curve – the curve shows no trade-off between sensi-
tivity and specificity. Table 3 presents the results of the
meta-analysis. The summary measures of specificity andBMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/6
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Study selection process Figure 1
Study selection process
2520 potentially relevant citations 
identified from all searches  
434 English and Spanish articles 
selected for full-text review 
109 articles reported inclusion of 
pleural specimens (fluid and/or pleural 
biopsy)
38 articles included in the meta-
analysis 
34 English 
4 Spanish 
2086 citations excluded after 
initial screen of citations 
369 articles met eligibility criteria (for 
all forms of tuberculosis) 
71 articles excluded 
56 No sensitivity and 
specificity data for 
pleural specimens 
12 Less than 10 pleural 
specimens 
3 Samples tested were 
pleural tissue/cytology 
specimens 
65 articles excluded after 
full-text screen 
17 No original data 
11 Fingerprinting study 
8 No comparison against 
reference standard 
7 Case reports
6 Description of new test 
methods
5 Reliability study 
3 Treatment monitoring 
study 
8 Other reasons BMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/6
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LR+ were very high and homogeneous. All other measures
were highly heterogeneous.
Commercial tests use different amplification methods
and target nucleic acid sequences: the Amplicor test
employs PCR technology to amplify the 16s rRNA target;
the LCx test employs ligase chain reaction to amplify the
38 kDa target; and the MTD test utilizes transcription-
mediated amplification to amplify rRNA. To account for
these differences, we further stratified commercial tests by
type (brand) of test. Four of the studies evaluated the
Amplicor test [28,42,54,55], four the LCx test
[37,44,46,52], and six evaluated the MTD test [26,33-
35,49,61]. Stratification reduced the overall heterogeneity
Table 1: Description of included studies – commercial testsa
Country, year Independent 
comparison
Cross-
Sectional 
study 
design
Double or 
single 
blind
Consecutive 
or random 
sample
Prospective 
data 
collection
Type of 
testb (target 
sequence)
Reference 
standardc
Study 
qualityd
No. of 
pleural 
specimens 
or subjects 
with TB/No. 
without TB
Sensitivity 
(95% CI)e
Specificity 
(95% CI)
AMPLICOR® 
Test
USA,[28] 1996 Yes Yes Unknown Unknown Unknown Amplicor 
(16s rRNA)
Culture Low 3/89 0.67 (0.13, 
0.98)
1.00 
(0.96, 
1.00)
Japan,[42] 2000 Yes Yes No Yes No Amplicor 
(16s rRNA)
Culture/
biopsy
Medium 33/42 0.27 (0.14, 
0.46)
0.98 
(0.86, 
1.00)
Germany,[54] 
1998
Yes Yes Yes Yes Yes Amplicor 
(16s rRNA)
Culture High 3/66 0.67 (0.13, 
0.98)
0.98 
(0.91, 
1.00)
USA,[55] 1998 Yes Yes Unknown Yes Yes Amplicor 
(16s rRNA)
Culture Medium 8/367 0.50 (0.18, 
0.82)
1.00 
(0.98, 
1.00)
LCx® Test
Argentina,[44] 
2001
Yes Yes Yes Yes Yes LCx (38 
kDa)
Culture/
clinical
High 16/186 0.69 (0.42, 
0.88)
0.96 
(0.92, 
0.98)
Spain,[46] 1998 Yes Yes Yes Yes Yes LCx (38 
kDa)
Culture/
biopsy
High 15/171 0.87(0.59, 
0.98)
0.98 
(0.95, 
1.00)
Finland,[52] 
2001
Partly Yes Yes Yes No LCx (38 
kDa)
Culture Medium 5/142 0.40 (0.07, 
0.83)
0.99 (0. 
95, 1.00)
Spain,[37] 1999 Yes Yes No Yes Yes LCx (38 
kDa)
Culture Medium 3/12 1.00 (0.29, 
1.00)
1.00 
(0.74, 
1.00)
MTD® Test
Spain,[26] 2001 Yes Yes No Yes Yes MTD-2 
(rRNA)
Culture/
clinical
Medium 5/96 0.20 (0.01, 
0.70)
0.98 
(0.92, 
1.00)
Germany,[33] 
1996
Yes Yes Yes No Partly MTD-1 
(rRNA)
Culture/
clinical
Medium 3/32 1.00 (0.29, 
1.00)
1.00 
(0.89, 
1.00)
Spain,[34] 1997 Yes Yes Yes No Yes MTD-1 
(rRNA)
Culture High 13/36 1.00 (0.75, 
1.00)
1.00 
(0.90, 
1.00)
Spain,[35] 1997 Yes Yes Yes No Yes MTD-1 
(rRNA)
Culture High 13/28 1.00 (0.75, 
1.00)
1.00 
(0.88, 
1.00)
Switzerland,[49] 
1996
Yes Yes Unknown Unknown Unknown MTD-1 
(rRNA)
Culture Low 4/61 0.50 (0.09, 
0.91)
0.95 
(0.85, 
0.99)
Netherlands,[61
] 1995
Yes Yes Unknown Yes Unknown MTD-1 
(rRNA)
Culture Medium 5/56 0.20 (0.01, 
0.70)
0.96 
(0.87, 
0.99)
aIncorporates additional information provided by authors of the primary studies bType of test: Amplicor (Roche Molecular Systems, Branchburg, 
NJ); MTD (Gen-Probe Inc, San Diego, CA); LCx (Abbott Laboratories, Abbott Park, IL) cReference standard: culture refers to culture of pleural 
fluid/sputum/biopsy; biopsy refers to pleural biopsy; clinical refers to data such as signs and symptoms, response to therapy, and pleural fluid analysis 
dSee text for description of quality assessment; eCI: Confidence IntervalBMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/6
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to some extent (Table 3 and Figure 2A). Although specifi-
city did not vary by type of kit, sensitivity did – the Ampli-
cor test had a lower sensitivity (0.37) than the LCx (0.72)
and MTD (0.77) tests. Since 5/6 studies on the MTD test
evaluated the first generation MTD-1 kit, there were insuf-
ficient numbers of MTD-2 studies to determine if the
enhanced MTD-2 test (licensed for use in smear-negative
respiratory specimens) performed better than the MTD-1
test.
Table 2: Description of included studies – In-house PCR testsa
Country, year Independent 
comparison
Cross-
sectional 
study 
design
Double or 
single blind
Consecutive 
or random 
sample
Prospectiv
e data 
collection
Type of testb 
sequence)
(target 
Reference 
standardc
Study 
qualityd
No. of 
pleural 
specimens 
or Subjects 
with TB/No. 
without TB
Sensitivity 
(95% CI)e
Specificity 
(95% CI)
Brazil,[24] 
2000
Yes No Yes Yes Partly PCR (16S 
rRNA)
Culture/
clinical
Medium 28/17 0.89 (0.71, 
0.97)
1.00 (0.80, 
1.00)
Spain,[25] 
2000
Yes No Yes Yes Yes PCR (IS6110) Culture/
clinical
Medium 9/16 0.89 (0.51, 
0.99)
1.00 (0.79, 
1.00)
China,[27] 
1996
Yes Yes Unknown Yes Unknown PCR (IS6110/
38 kDa)
Culture Medium 25/76 0.44 (0.25, 
0.65)
0.99 (0.92, 
1.00)
India,[29] 
1998
Yes No Yes Unknown Yes PCR (MPB64) Culture/
clinical
Medium 28/16 0.61 (0.41, 
0.78)
0.94 (0.68, 
1.00)
France,[30] 
1992
Yes No No No Partly PCR (IS6110) Culture/
biopsy
Low 15/10 0.60 (0.33, 
0.82)
1.00 (0.69, 
1.00)
France,[30] 
1992
Yes No No No Partly PCR (65 kDa) Culture/
biopsy
Low 15/10 0.20 (0.05, 
0.48)
1.00 (0.69, 
1.00)
S. Africa,[31] 
1992 Yes
Yes Yes Yes Yes Yes PCR (336 bp 
repetitive 
sequence)
Culture/
biopsy
High 50/31 0.82 (0.68, 
0.91)
0.77 (0.59, 
0.90)
S. Africa,[32] 
1990 Yes
Yes Yes Unknown Unknown Unknown PCR (336 bp 
repetitive 
sequence)
Culture Medium 11/5 1.00 (0.72, 
1.00)
1.00 (0.48, 
1.00)
India,[36] 
2001
Yes Yes Yes No Yes PCR (IS6110) Culture Medium 4/26 0.25 (0.01, 
0.78)
0.96 (0.79, 
1.00)
Chile,[38] 
1993
Yes No Yes Unknown Unknown PCR (65 kDa) Culture/
microscop
y
Medium 15/11 0.93 (0.66, 
1.00)
1.00 (0.72, 
1.00)
Mexico et 
al,[39] 2001
Yes Yes Yes Yes Yes PCR (465 bp 
sequence)
Culture High 3/12 0.33 (0.02, 
0.87)
0.83 (0. 
51, 0.97)
France,[40] 
1996
Yes No No Yes Yes PCR (IS6110) Culture/
biopsy
Medium 17/25 0.76 (0.50, 
0.92)
1.00 (0.86, 
1.00)
Brazil,[41] 
2000
Yes Yes Yes Yes Partly PCR (MPB64) Culture/
biopsy
High 19/11 0.68 (0.44, 
0.86)
0.91 (0.57, 
0.99)
Japan,[43] 
1993
Yes Yes Unknown Unknown Unknown PCR (38 kDa) Culture Low 5/105 0.80 (0.30, 
0.99)
0.93 (0.86, 
0.97)
India,[45] 
2001
Yes Yes Yes Unknown No PCR (150 bp 
sequence)
Microscop
y/biopsy
High 20/40 0.70 (0.46, 
0.87)
1.00 (0.91, 
1.00)
Taiwan,[47] 
1990
Yes Yes Unknown Unknown Unknown PCR (65 kDa) Culture Medium 11/37 1.00 (0.72, 
1.00)
0.78 (0.61, 
0.90)
India,[48] 
2000
Yes Yes Unknown Unknown Unknown PCR (IS6110/
TRC4)
Culture/
microscop
y
Medium 30/20 1.00 (0.88, 
1.00)
0.70 (0.46, 
0.87)
Mexico,[50] 
2000
Yes No Yes Yes Yes PCR (IS6110) Culture/
biopsy
High 17/56 0.94 (0.69, 
1.00)
1.00 (0.94, 
1.00)
Spain,[51] 
1995
Yes No Yes Yes Yes PCR (IS6110) Culture/
biopsy
High 21/86 0.81 (0.58, 
0.94)
0.98 (0.91, 
1.00)
Thailand,[53] 
2000
Yes Yes Unknown Yes Yes PCR (16S 
rRNA)
Culture/
biopsy
High 36/62 0.72 (0.55, 
0.85)
0.53 (0.40, 
0.66)
Singapore,[57
] 1995
Yes No Unknown Unknown Unknown PCR (IS6110) Culture/
biopsy
Low 10/13 0.70 (0.36, 
0.92)
1.00 (0.75, 
1.00)
Singapore,[57
] 1995
Yes No Unknown Unknown Unknown PCR (MPB64) Culture/
biopsy
Low 10/13 0.70 (0.36, 
0.92)
1.00 (0.75, 
1.00)
Singapore,[56
] 1997
Yes Yes Yes Yes Yes PCR (IS6110) Culture/
clinical
High 16/49 1.00 (0.79, 
1.00)
0.88 (0.75, 
0.95)
India,[58] 
1995
Yes No Yes No Yes PCR (150 bp 
sequence)
Clinical/
biopsy
Medium 38/29 0.63 (0.46, 
0.78)
0.93 (0.76, 
0.99)
Colombia,[59
] 2000
Yes Yes Yes Yes No PCR (IS6110) Culture/
biopsy
High 42/70 0.74 (0.58, 
0.86)
0.90 (0.80, 
0.96)
Spain,[60] 
1998
Yes Yes Yes No Yes PCR (IS6110) Culture/
biopsy
High 33/98 0.42 (0.26, 
0.61)
0.99 (0.94, 
1.00)
aIncorporates additional information provided by authors of the primary studies bType of test: PCR: polymerase chain reaction cReference standard: 
culture refers to culture of pleural fluid/sputum/biopsy; biopsy refers to pleural biopsy; clinical refers to data such as signs and symptoms, response 
to therapy, and pleural fluid analysis dSee text for description of quality assessment eCI: Confidence IntervalBMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/6
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Forest plots of estimates of sensitivity and specificity in studies with commercial and in-house tests Figure 2
Forest plots of estimates of sensitivity and specificity in studies with commercial and in-house tests. The point estimates of sen-
sitivity and specificity from each study are shown as solid circles. Error bars are 95% confidence intervals. Numbers indicate 
the studies cited in the bibliography. Pooled estimates are summary random effects estimates with 95% confidence intervals.
(A) Commercial Tests 
(B) In-house Tests BMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/6
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Summary Receiver Operating Characteristic curves for commercial and in-house tests Figure 3
Summary Receiver Operating Characteristic curves for commercial and in-house tests Each solid circle represents each study 
in the meta-analysis. The size of each study is indicated by the size of the solid circle. The weighted (dark line) and unweighted 
(thin line) regression SROC curves summarize the overall diagnostic accuracy.
(A) Commercial Tests 
(B) In-house Tests BMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/6
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Diagnostic accuracy of in-house tests
Figure 2(B) displays the sensitivity and specificity esti-
mates from each of the 26 studies using in-house tests.
Both sensitivity (range 0.20–1.0) and specificity (range
0.53–1.0) estimates were highly variable. All summary
measures were grossly heterogeneous (Table 3) and there-
fore would not be appropriately summarized. The SROC
curve [Figure 3(B)] displays a ROC-type trade-off between
sensitivity and specificity.
We performed stratified analyses to identify sources of
heterogeneity among in-house tests. Table 4 presents two
factors that appeared most strongly associated with the
observed heterogeneity. Studies that employed a case-con-
trol design produced diagnostic odds ratio estimates
nearly 2.4 times higher than studies that employed a
cross-sectional design. Studies with PCR tests that used
the IS6110 target sequence produced diagnostic odds
ratio estimates 2.5 times higher than studies that used
PCR tests with other targets. However, even after stratify-
ing on study design and target sequence, considerable
unexplained heterogeneity persisted in all the summary
measures. The shape of the SROC curve suggested that var-
iability in diagnostic thresholds (cut-points) across stud-
ies could partly explain the heterogeneity.
Publication bias
In the subgroup with commercial tests, the Egger test was
not statistically significant (p = 0.55). However, in the in-
house tests subgroup the Egger test was significant (p =
0.002), with an asymmetric funnel plot (figure 4) – evi-
dence in favour of potential publication bias.
Discussion
Since conventional tests are not always helpful in estab-
lishing a diagnosis of tuberculous pleuritis, several rapid
tests and biomarkers have been evaluated: Adenosine
Deaminase (ADA) [12,14,45,51,59,62], Interferon-γ
(IFN-γ) [59,60,62,63], lysozyme [62], soluble interleukin
2 receptors [63], and NAA tests [24-61]. There has been an
explosion of studies evaluating these rapid tests, and sys-
tematic reviews and meta-analyses are necessary to syn-
Table 3: Summary accuracy measures for commercial and in-house tests
Measure of test accuracy Pooled summary measurea (95% CI) Test for heterogeneityb p value
All Commercial Tests [N = 14]
Sensitivity 0.62 (0.43, 0.77) <0.001
Specificity 0.98 (0.96, 0.98) 0.12
Positive Likelihood Ratio (LR+) 25.4 (16.2, 40.0) 0.46
Negative likelihood Ratio (LR-) 0.40 (0.24, 0.67) <0.001
Diagnostic odds ratio (DOR) 80.9 (34.4, 190.4) 0.09
Amplicor [N = 4]
Sensitivity 0.37(0.24, 0.52) 0.18
Specificity 0.99 (0.97, 1.0) 0.12
Positive Likelihood Ratio (LR+) 52.8 (11.8, 236.2) 0.14
Negative likelihood Ratio (LR-) 0.59 (0.37, 0.95) 0.20
Diagnostic odds ratio (DOR) 105.5 (15.1, 733.9) 0.10
LCx [N = 4]
Sensitivity 0.72 (0.54, 0.84) 0.12
Specificity 0.97 (0.95, 0.98) 0.53
Positive Likelihood Ratio (LR+) 25.6 (14.1, 46.4) 0.57
Negative likelihood Ratio (LR-) 0.32 (0.14, 0.68) 0.09
Diagnostic odds ratio (DOR) 93.2 (35.6, 243.7) 0.38
MTD [N = 6]
Sensitivity 0.77 (0.62, 0.88) <0.001
Specificity 0.98 (0.96, 0.99) 0.66
Positive Likelihood Ratio (LR+) 17.4 (6.1, 49.7) 0.26
Negative likelihood Ratio (LR-) 0.31 (0.09, 1.03) <0.001
Diagnostic odds ratio (DOR) 72.9 (9.9, 533.4) 0.03
In-house Tests [N = 26]
Sensitivity 0.71 (0.63, 0.78) <0.001
Specificity 0.93 (0.88, 0.96) <0.001
Positive Likelihood Ratio (LR+) 9.7 (5.7, 16.6) <0.001
Negative likelihood Ratio (LR-) 0.32 (0.23, 0.43) <0.001
Diagnostic odds ratio (DOR) 42.4 (22.2, 81.1) <0.001
aRandom effects model; bChi-square or Fisher's exact test for heterogeneityBMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/6
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Table 4: Stratified analyses for the evaluation of heterogeneity in studies with in-house tests
Subgroup Summary Diagnostic Odds Ratio (95% CI)a Test for heterogeneityb p value
Study design
Case-control (N = 12 studies) 68.3 (31.8, 146.5) 0.39
Cross-sectional (N = 14 studies) 28.7 (12.3, 66.9) 0.002
Target sequence
IS6110 (N = 12 studies) 62.4 (32.8, 118.7) 0.42
Other target sequences (N = 14 studies) 25.5 (10.6, 61.3) 0.006
aConfidence interval bChi-square test for heterogeneity
Funnel plot for evaluation of publication bias in studies with in-house tests Figure 4
Funnel plot for evaluation of publication bias in studies with in-house tests The funnel graph plots the log of the diagnostic odds 
ratio (DOR) against the standard error of the log of the DOR (an indicator of sample size). Each open circle represents each 
study in the meta-analysis. The line in the center indicates the summary DOR. In the absence of publication bias, the DOR esti-
mates from smaller studies are expected to be scattered above and below the summary estimate, producing a triangular or 
funnel shape. The funnel plots appear asymmetric – smaller studies with low DOR estimates are missing – indicating a potential 
for publication bias. The Egger test for publication bias was statistically significant (p = 0.002) in the in-house test subgroup.
Begg's funnel plot with pseudo 95% confidence limits
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thesize this growing body of literature. A recent meta-
analysis summarized the evidence on ADA and IFN-γ for
the diagnosis of tuberculous pleuritis [64]. Both ADA and
IFN-γ tests were found to be reasonably accurate at detect-
ing tuberculous pleuritis. Our meta-analysis summarizes
the evidence on accuracy of NAA tests in the diagnosis of
tuberculous pleuritis.
Principal findings
The role of NAA tests has been reasonably well defined in
pulmonary tuberculosis [15,16,65], and guidelines exist
for testing of respiratory specimens [16]. In contrast, their
role in the evaluation of specimens such as pleural fluid is
not clear. Our results indicate that commercial NAA tests
have high specificity and positive likelihood ratios. These
test properties suggest a potential role for commercial
tests in confirming (ruling in) the diagnosis of tubercu-
lous pleuritis. These tests, however, have low and widely
varying sensitivities – test properties that make them
unhelpful in ruling out TB. Potential explanations for the
low sensitivity include a low bacillary load in pleural
fluid, or the presence of substances in the pleural fluid
that inhibit amplification [65]. Some authors have sug-
gested that pleural fluids should be tested with NAA meth-
ods after the specimens are adequately pre-treated to
remove inhibitors [65]. All commercial kits appear to be
designed to maximize only specificity. The MTD and LCx
kits appear to have higher sensitivity than the Amplicor
test. This comparison should be interpreted cautiously
because it is based on few studies. Studies that directly
compare these commercial tests (head-to-head) within
the same study population are required to confirm these
observations. The most important finding regarding in-
house PCR is the significant heterogeneity across studies.
Clinical implications
To interpret the summary measures in a clinical context,
consider a patient from a high incidence setting (e.g.
countries such as Spain or Malaysia) who is estimated to
have a 50% probability of pleural TB after clinical evalua-
tion, and is evaluated with either the MTD test (LR+ of
17.4 and LR- of 0.31) or the Amplicor test (LR+ of 52.8
and LR- of 0.59). A LR+ of 17.4 for the MTD test suggests
that patients with tuberculous pleuritis have a 17-fold
higher chance of being MTD test positive as compared to
patients without TB. If the MTD test were positive, the
likelihood that this patient has TB increases from 50% to
95%, a probability that is sufficiently high to justify initi-
ation of anti-tuberculosis treatment. A positive Amplicor
test will raise the probability of TB from 50% to 97%. In
contrast, if the MTD test result were negative, there is still
a 24% chance that this patient has TB, probably not suffi-
ciently low to rule out TB with confidence. In case of the
Amplicor test, a negative test will reduce the probability
from 50% to 40%, again not low enough to rule out TB.
Consider another patient from a low incidence setting
(e.g. countries such as the USA), where the baseline prob-
ability of TB is low (e.g. 5%). If MTD test were positive, the
likelihood that this patient has TB increases from 5% to
48%, a probability that justifies further investigation. A
positive Amplicor test will raise the probability of TB from
5% to 75%. If the MTD® test result were negative, the base-
line probability changes from 5% to 2%, a negligible shift
that is unlikely to be helpful in clinical decision-making.
In case of the Amplicor test, the probability changes from
5% to 4%. These examples illustrate the impact of the
baseline prevalence (pre-test probability) on predictive
values of the tests.
The accuracy of in-house PCR was heterogeneous across
studies, and thus meaningful summary measures of accu-
racy could not be determined. The clinical implications,
therefore, will depend on the setting. Institutions that use
in-house PCR will have to rely on local data to decide on
its accuracy and clinical applicability. In general, PCR for
tuberculosis is known to have poor inter-laboratory repro-
ducibility [66].
In addition to the effect of diagnostic thresholds seen in
the SROC plot, we identified two factors that were associ-
ated with heterogeneity among in-house tests: use of a
case-control design, and use of the IS6110 target
sequence. Case-control studies sample patients from the
extreme ends of the clinical spectrum (an ideal, "extreme
contrast" setting). If the sensitivity of a test is evaluated in
seriously diseased subjects, and specificity in healthy indi-
viduals, both measures will overestimate the true diagnos-
tic accuracy [67]. Empiric research suggests that case-
control studies overestimate the diagnostic odds ratio by
a factor of 3, when compared to cross-sectional studies
[68]. Future studies of NAA tests could reduce this bias by
avoiding the case-control design and recruiting consecu-
tive series of patients in whom the test is clinically indi-
cated (a realistic, "clinical practice" setting). The IS6110
target sequence is widely used in M. tuberculosis finger-
printing [69]. Because this target is specific to the M. tuber-
culosis  complex, and because it is usually present as
multiple copies in the genome, PCR tests using this target
might be more sensitive. Further research is underway to
confirm this finding, in a larger meta-analysis of in-house
PCR in the diagnosis of pulmonary tuberculosis.
Previous meta-analyses of NAA test accuracy
Our data are consistent with the results of two previous
meta-analyses on the accuracy of NAA tests. Sarmiento
and colleagues summarized the accuracy of PCR in the
diagnosis of smear-negative pulmonary TB [70]. Their
meta-analysis of 50 studies showed that both sensitivity
and specificity estimates were heterogeneous. They con-
cluded that PCR is not consistently accurate enough to beBMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/6
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routinely recommended for the diagnosis of smear-nega-
tive TB. Our previous meta-analysis of 49 studies summa-
rized the accuracy of NAA tests in the diagnosis of
tuberculous meningitis [71]. Commercial tests were
found to have high overall specificity (0.98) and low sen-
sitivity (0.56). The accuracy of in-house PCR was not
determined because of heterogeneity in study results.
Limitations of the review
Our review has limitations. Our analysis lacks data on the
incremental gain of NAA tests over and above the diagnos-
tic performance achieved by using only conventional
methods or other rapid tests like ADA and IFN-γ. The pri-
mary studies in our review did not report such data. Also,
few studies in our review directly compared the NAA test
against tests such as ADA and IFN-γ[45,51,59]. Only one
study [59] directly compared the three tests in the same
population, and showed that ADA, IFN-γand PCR were
88%, 86%, and 74% sensitive respectively, and 86%,
97%, and 90% specific respectively, for culture or biopsy-
confirmed pleural TB. Since we did not include tests such
as ADA and IFN-γ in our literature searches, our review
cannot identify the most accurate test. Also, publication
bias was a concern with the in-house tests. Exclusion of
studies published in languages other than English and
Spanish could have contributed to this potential bias.
Conclusions
In summary, our data suggest a potentially useful role for
commercial NAA tests in confirming a diagnosis of
tuberculous pleuritis. However, commercial kits have low
and varying sensitivities, and therefore should not be used
for excluding a diagnosis of tuberculous pleuritis. NAA
test results, therefore, cannot replace conventional tests;
they need to be interpreted in parallel with clinical find-
ings and results of conventional tests. The accuracy of in-
house PCR tests is poorly defined because of heterogene-
ity in study results. Clinically useful summary measures
cannot be estimated for in-house PCR tests; their clinical
applicability remains unclear.
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